Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis
暂无分享,去创建一个
O. Inatomi | A. Andoh | S. Bamba | Y. Fujiyama | T. Tsujikawa | M. Sasaki | Yusuke Koizumi | T. Nakahara | Y. Saitoh
[1] K Rowland-Yeo,et al. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[2] R. Modigliani,et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open‐label multicentre study , 2003, Alimentary pharmacology & therapeutics.
[3] A. Forbes,et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial , 2003, Gut.
[4] R. Cohen,et al. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. , 1999, Inflammatory bowel diseases.
[5] W. Sandborn. A Critical Review of Cyclosporine Therapy in Inflammatory Bowel Disease , 1995 .
[6] S. Hanauer,et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.
[7] G. Actis,et al. Continuously Infused Cyclosporine at Low Dose Is Sufficient to Avoid Emergency Colectomy in Acute Attacks of Ulcerative Colitis Without the Need for High‐Dose Steroids , 1993, Journal of clinical gastroenterology.
[8] M. Selgrade,et al. Correlation between chemical suppression of natural killer cell activity in mice and susceptibility to cytomegalovirus: rationale for applying murine cytomegalovirus as a host resistance model and for interpreting immunotoxicity testing in terms of risk of disease. , 1992, Journal of toxicology and environmental health.
[9] T. Yao,et al. An index of disease activity in patients with ulcerative colitis. , 1992, The American journal of gastroenterology.